Work

Supplementary Figures S1-3 from Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure 1: MRI images and tumor volume measurements. Supplementary Figure 2: Mouse body weight during drug treatment. Supplementary Figure 3: Results of molecular studies of resistant tumors.

DOI: 10.1158/1078-0432.22458753.v1

Authors: Valentina Pirazzoli, Deborah Ayeni, Catherine B. Meador, Basavaraju G. Sanganahalli, Fahmeed Hyder, Elisa de Stanchina, Sarah B. Goldberg, William Pao, Katerina Politi

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361918052

Cites:

Cited by:

Related to: 10